Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study.

Neuro-oncology advances

Meijer AJM, Fiocco MF, Janssens GO, Clemens E, Tissing WJE, Loonen JJ, van Dulmen-den Broeder E, de Vries ACH, Bresters D, Versluys B, Ronckers CM, Kremer LCM, van der Pal HJ, Neggers SJCMM, van der Heiden-van der Loo M, Stokroos RJ, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM.
PMID: 33196041
Neurooncol Adv. 2020 Sep 15;2(1):vdaa122. doi: 10.1093/noajnl/vdaa122. eCollection 2020.

BACKGROUND: Tinnitus is a serious late effect of childhood cancer treatment. The aim of this study was to determine the occurrence and risk factors for tinnitus in a national cohort of childhood cancer survivors (CCS).METHODS: Data were collected within...

Cite
Meijer AJM, Fiocco MF, Janssens GO, et al. Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study. Neurooncol Adv. 2020;2(1):vdaa122doi: 10.1093/noajnl/vdaa122.
Meijer, A. J. M., Fiocco, M. F., Janssens, G. O., Clemens, E., Tissing, W. J. E., Loonen, J. J., van Dulmen-den Broeder, E., de Vries, A. C. H., Bresters, D., Versluys, B., Ronckers, C. M., Kremer, L. C. M., van der Pal, H. J., Neggers, S. J. C. M. M., van der Heiden-van der Loo, M., Stokroos, R. J., Hoetink, A. E., van Grotel, M., & van den Heuvel-Eibrink, M. M. (2020). Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study. Neuro-oncology advances, 2(1), vdaa122. https://doi.org/10.1093/noajnl/vdaa122
Meijer, Annelot J M, et al. "Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study." Neuro-oncology advances vol. 2,1 (2020): vdaa122. doi: https://doi.org/10.1093/noajnl/vdaa122
Meijer AJM, Fiocco MF, Janssens GO, Clemens E, Tissing WJE, Loonen JJ, van Dulmen-den Broeder E, de Vries ACH, Bresters D, Versluys B, Ronckers CM, Kremer LCM, van der Pal HJ, Neggers SJCMM, van der Heiden-van der Loo M, Stokroos RJ, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM. Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study. Neurooncol Adv. 2020 Sep 15;2(1):vdaa122. doi: 10.1093/noajnl/vdaa122. eCollection 2020. PMID: 33196041; PMCID: PMC7648591.
Copy Download .nbib Format: NLM
The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments.

Cancer

Meijer AJM, Li KH, Brooks B, Clemens E, Ross CJ, Rassekh SR, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM, Carleton BC.
PMID: 34490624
Cancer. 2022 Jan 01;128(1):169-179. doi: 10.1002/cncr.33848. Epub 2021 Sep 07.

BACKGROUND: Ototoxicity is a common adverse event of cisplatin treatment. The authors investigated the development of cisplatin-induced hearing loss (CIHL) over time in children with cancer by age and examined the influence of other clinical characteristics on the course...

Cite
Meijer AJM, Li KH, Brooks B, et al. The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments. Cancer. 2021;128(1):169-179doi: 10.1002/cncr.33848.
Meijer, A. J. M., Li, K. H., Brooks, B., Clemens, E., Ross, C. J., Rassekh, S. R., Hoetink, A. E., van Grotel, M., van den Heuvel-Eibrink, M. M., & Carleton, B. C. (2022). The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments. Cancer, 128(1), 169-179. https://doi.org/10.1002/cncr.33848
Meijer, Annelot J M, et al. "The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments." Cancer vol. 128,1 (2022): 169-179. doi: https://doi.org/10.1002/cncr.33848
Meijer AJM, Li KH, Brooks B, Clemens E, Ross CJ, Rassekh SR, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM, Carleton BC. The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments. Cancer. 2022 Jan 01;128(1):169-179. doi: 10.1002/cncr.33848. Epub 2021 Sep 07. PMID: 34490624.
Copy Download .nbib Format: NLM
Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review.

JAC-antimicrobial resistance

Diepstraten FA, Hoetink AE, van Grotel M, Huitema ADR, Stokroos RJ, van den Heuvel-Eibrink MM, Meijer AJM.
PMID: 34917943
JAC Antimicrob Resist. 2021 Dec 14;3(4):dlab184. doi: 10.1093/jacamr/dlab184. eCollection 2021 Dec.

BACKGROUND: Ototoxicity has been reported after administration of aminoglycosides and glycopeptides.OBJECTIVES: To identify available evidence for the occurrence and determinants of aminoglycoside- and glycopeptide-related ototoxicity in children.MATERIALS AND METHODS: Systematic electronic literature searches that combined ototoxicity (hearing loss, tinnitus...

Cite
Diepstraten FA, Hoetink AE, van Grotel M, et al. Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review. JAC Antimicrob Resist. 2021;3(4):dlab184doi: 10.1093/jacamr/dlab184.
Diepstraten, F. A., Hoetink, A. E., van Grotel, M., Huitema, A. D. R., Stokroos, R. J., van den Heuvel-Eibrink, M. M., & Meijer, A. J. M. (2021). Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review. JAC-antimicrobial resistance, 3(4), dlab184. https://doi.org/10.1093/jacamr/dlab184
Diepstraten, F A, et al. "Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review." JAC-antimicrobial resistance vol. 3,4 (2021): dlab184. doi: https://doi.org/10.1093/jacamr/dlab184
Diepstraten FA, Hoetink AE, van Grotel M, Huitema ADR, Stokroos RJ, van den Heuvel-Eibrink MM, Meijer AJM. Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review. JAC Antimicrob Resist. 2021 Dec 14;3(4):dlab184. doi: 10.1093/jacamr/dlab184. eCollection 2021 Dec. PMID: 34917943; PMCID: PMC8669239.
Copy Download .nbib Format: NLM
The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments.

Cancer

Meijer AJM, Li KH, Brooks B, Clemens E, Ross CJ, Rassekh SR, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM, Carleton BC.
PMID: 34490624
Cancer. 2021 Sep 07; doi: 10.1002/cncr.33848. Epub 2021 Sep 07.

BACKGROUND: Ototoxicity is a common adverse event of cisplatin treatment. The authors investigated the development of cisplatin-induced hearing loss (CIHL) over time in children with cancer by age and examined the influence of other clinical characteristics on the course...

Cite
Meijer AJM, Li KH, Brooks B, et al. The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments. Cancer. 2021;doi: 10.1002/cncr.33848.
Meijer, A. J. M., Li, K. H., Brooks, B., Clemens, E., Ross, C. J., Rassekh, S. R., Hoetink, A. E., van Grotel, M., van den Heuvel-Eibrink, M. M., & Carleton, B. C. (2021). The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments. Cancer, . https://doi.org/10.1002/cncr.33848
Meijer, Annelot J M, et al. "The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments." Cancer vol. (2021). doi: https://doi.org/10.1002/cncr.33848
Meijer AJM, Li KH, Brooks B, Clemens E, Ross CJ, Rassekh SR, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM, Carleton BC. The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments. Cancer. 2021 Sep 07; doi: 10.1002/cncr.33848. Epub 2021 Sep 07. PMID: 34490624.
Copy Download .nbib Format: NLM
Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report.

JAMA oncology

Meijer AJM, van den Heuvel-Eibrink MM, Brooks B, Am Zehnhoff-Dinnesen AG, Knight KR, Freyer DR, Chang KW, Hero B, Papadakis V, Frazier AL, Blattmann C, Windsor R, Morland B, Bouffet E, Rutkowski S, Tytgat GAM, Geller JI, Hunter LL, Sung L, Calaminus G, Carleton BC, Helleman HW, Foster JH, Kruger M, Cohn RJ, Landier W, van Grotel M, Brock PR, Hoetink AE, Rajput KM.
PMID: 34383016
JAMA Oncol. 2021 Oct 01;7(10):1550-1558. doi: 10.1001/jamaoncol.2021.2697.

IMPORTANCE: Ototoxicity is an irreversible direct and late effect of certain childhood cancer treatments. Audiologic surveillance during therapy as part of the supportive care pathway enables early detection of hearing loss, decision-making about ongoing cancer treatment, and, when applicable,...

Cite
Meijer AJM, van den Heuvel-Eibrink MM, Brooks B, et al. Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report. JAMA Oncol. 2021;7(10):1550-1558doi: 10.1001/jamaoncol.2021.2697.
Meijer, A. J. M., van den Heuvel-Eibrink, M. M., Brooks, B., Am Zehnhoff-Dinnesen, A. G., Knight, K. R., Freyer, D. R., Chang, K. W., Hero, B., Papadakis, V., Frazier, A. L., Blattmann, C., Windsor, R., Morland, B., Bouffet, E., Rutkowski, S., Tytgat, G. A. M., Geller, J. I., Hunter, L. L., Sung, L., Calaminus, G., Carleton, B. C., Helleman, H. W., Foster, J. H., Kruger, M., Cohn, R. J., Landier, W., van Grotel, M., Brock, P. R., Hoetink, A. E., Rajput, K. M. (2021). Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report. JAMA oncology, 7(10), 1550-1558. https://doi.org/10.1001/jamaoncol.2021.2697
Meijer, Annelot J M, et al. "Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report." JAMA oncology vol. 7,10 (2021): 1550-1558. doi: https://doi.org/10.1001/jamaoncol.2021.2697
Meijer AJM, van den Heuvel-Eibrink MM, Brooks B, Am Zehnhoff-Dinnesen AG, Knight KR, Freyer DR, Chang KW, Hero B, Papadakis V, Frazier AL, Blattmann C, Windsor R, Morland B, Bouffet E, Rutkowski S, Tytgat GAM, Geller JI, Hunter LL, Sung L, Calaminus G, Carleton BC, Helleman HW, Foster JH, Kruger M, Cohn RJ, Landier W, van Grotel M, Brock PR, Hoetink AE, Rajput KM. Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report. JAMA Oncol. 2021 Oct 01;7(10):1550-1558. doi: 10.1001/jamaoncol.2021.2697. PMID: 34383016.
Copy Download .nbib Format: NLM
Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review.

JAC-antimicrobial resistance

Diepstraten FA, Hoetink AE, van Grotel M, Huitema ADR, Stokroos RJ, van den Heuvel-Eibrink MM, Meijer AJM.
PMID: 34917943
JAC Antimicrob Resist. 2021 Dec 14;3(4):dlab184. doi: 10.1093/jacamr/dlab184. eCollection 2021 Dec.

BACKGROUND: Ototoxicity has been reported after administration of aminoglycosides and glycopeptides.OBJECTIVES: To identify available evidence for the occurrence and determinants of aminoglycoside- and glycopeptide-related ototoxicity in children.MATERIALS AND METHODS: Systematic electronic literature searches that combined ototoxicity (hearing loss, tinnitus...

Cite
Diepstraten FA, Hoetink AE, van Grotel M, et al. Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review. JAC Antimicrob Resist. 2021;3(4):dlab184doi: 10.1093/jacamr/dlab184.
Diepstraten, F. A., Hoetink, A. E., van Grotel, M., Huitema, A. D. R., Stokroos, R. J., van den Heuvel-Eibrink, M. M., & Meijer, A. J. M. (2021). Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review. JAC-antimicrobial resistance, 3(4), dlab184. https://doi.org/10.1093/jacamr/dlab184
Diepstraten, F A, et al. "Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review." JAC-antimicrobial resistance vol. 3,4 (2021): dlab184. doi: https://doi.org/10.1093/jacamr/dlab184
Diepstraten FA, Hoetink AE, van Grotel M, Huitema ADR, Stokroos RJ, van den Heuvel-Eibrink MM, Meijer AJM. Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review. JAC Antimicrob Resist. 2021 Dec 14;3(4):dlab184. doi: 10.1093/jacamr/dlab184. eCollection 2021 Dec. PMID: 34917943; PMCID: PMC8669239.
Copy Download .nbib Format: NLM
The Dutch Multidisciplinary Occupational Health Guideline to Enhance Work Participation Among Low Back Pain and Lumbosacral Radicular Syndrome Patients.

Journal of occupational rehabilitation

Luites JWH, Kuijer PPFM, Hulshof CTJ, Kok R, Langendam MW, Oosterhuis T, Anema JR, Lapré-Utama VP, Everaert CPJ, Wind H, Smeets RJEM, van Zaanen Y, Hoebink EA, Voogt L, de Hoop W, Boerman DH, Hoving JL.
PMID: 34313903
J Occup Rehabil. 2021 Jul 27; doi: 10.1007/s10926-021-09993-4. Epub 2021 Jul 27.

Purpose Based on current scientific evidence and best practice, the first Dutch multidisciplinary practice guideline for occupational health professionals was developed to stimulate prevention and enhance work participation in patients with low back pain (LBP) and lumbosacral radicular syndrome...

Cite
Luites JWH, Kuijer PPFM, Hulshof CTJ, et al. The Dutch Multidisciplinary Occupational Health Guideline to Enhance Work Participation Among Low Back Pain and Lumbosacral Radicular Syndrome Patients. J Occup Rehabil. 2021;doi: 10.1007/s10926-021-09993-4.
Luites, J. W. H., Kuijer, P. P. F. M., Hulshof, C. T. J., Kok, R., Langendam, M. W., Oosterhuis, T., Anema, J. R., Lapré-Utama, V. P., Everaert, C. P. J., Wind, H., Smeets, R. J. E. M., van Zaanen, Y., Hoebink, E. A., Voogt, L., de Hoop, W., Boerman, D. H., & Hoving, J. L. (2021). The Dutch Multidisciplinary Occupational Health Guideline to Enhance Work Participation Among Low Back Pain and Lumbosacral Radicular Syndrome Patients. Journal of occupational rehabilitation, . https://doi.org/10.1007/s10926-021-09993-4
Luites, J W H, et al. "The Dutch Multidisciplinary Occupational Health Guideline to Enhance Work Participation Among Low Back Pain and Lumbosacral Radicular Syndrome Patients." Journal of occupational rehabilitation vol. (2021). doi: https://doi.org/10.1007/s10926-021-09993-4
Luites JWH, Kuijer PPFM, Hulshof CTJ, Kok R, Langendam MW, Oosterhuis T, Anema JR, Lapré-Utama VP, Everaert CPJ, Wind H, Smeets RJEM, van Zaanen Y, Hoebink EA, Voogt L, de Hoop W, Boerman DH, Hoving JL. The Dutch Multidisciplinary Occupational Health Guideline to Enhance Work Participation Among Low Back Pain and Lumbosacral Radicular Syndrome Patients. J Occup Rehabil. 2021 Jul 27; doi: 10.1007/s10926-021-09993-4. Epub 2021 Jul 27. PMID: 34313903.
Copy Download .nbib Format: NLM
Video-assisted thoracoscopic surgery as a diagnostic and therapeutic instrument in non-tubercular spondylodiscitis.

International journal of spine surgery

Détillon D, de Groot H, Hoebink E, Versteylen R, Veen E.
PMID: 26609510
Int J Spine Surg. 2015 Oct 26;9:55. doi: 10.14444/2055. eCollection 2015.

BACKGROUND: Spondylodiscitis refers to an infection of one or more intervertebral disks and vertebrae, most commonly caused by tuberculosis. Initial therapy for spondylodiscitis is drug treatment. Indications for surgical treatment include compression of neural elements, spinal instability or severe...

Cite
Détillon D, de Groot H, Hoebink E, et al. Video-assisted thoracoscopic surgery as a diagnostic and therapeutic instrument in non-tubercular spondylodiscitis. Int J Spine Surg. 2015;9:55doi: 10.14444/2055.
Détillon, D., de Groot, H., Hoebink, E., Versteylen, R., & Veen, E. (2015). Video-assisted thoracoscopic surgery as a diagnostic and therapeutic instrument in non-tubercular spondylodiscitis. International journal of spine surgery, 955. https://doi.org/10.14444/2055
Détillon, Deniece, et al. "Video-assisted thoracoscopic surgery as a diagnostic and therapeutic instrument in non-tubercular spondylodiscitis." International journal of spine surgery vol. 9 (2015): 55. doi: https://doi.org/10.14444/2055
Détillon D, de Groot H, Hoebink E, Versteylen R, Veen E. Video-assisted thoracoscopic surgery as a diagnostic and therapeutic instrument in non-tubercular spondylodiscitis. Int J Spine Surg. 2015 Oct 26;9:55. doi: 10.14444/2055. eCollection 2015. PMID: 26609510; PMCID: PMC4657603.
Copy Download .nbib Format: NLM
An In Vitro Pilot Study Comparing the Novel HemoClear Gravity-Driven Microfiltration Cell Salvage System with the Conventional Centrifugal XTRA™ Autotransfusion Device.

Anesthesiology research and practice

Hoetink A, Scherphof SF, Mooi FJ, Westers P, van Dijk J, van de Leur SJ, Nierich AP.
PMID: 32963523
Anesthesiol Res Pract. 2020 Sep 08;2020:9584186. doi: 10.1155/2020/9584186. eCollection 2020.

BACKGROUND: In 2013, the World Health Organization reported a shortage of 17 million red blood cell units, a number that remains growing. Acts to relieve this shortage have primarily focused on allogeneic blood collection. Nevertheless, autologous transfusion can partially...

Cite
Hoetink A, Scherphof SF, Mooi FJ, et al. An In Vitro Pilot Study Comparing the Novel HemoClear Gravity-Driven Microfiltration Cell Salvage System with the Conventional Centrifugal XTRA™ Autotransfusion Device. Anesthesiol Res Pract. 2020;2020:9584186doi: 10.1155/2020/9584186.
Hoetink, A., Scherphof, S. F., Mooi, F. J., Westers, P., van Dijk, J., van de Leur, S. J., & Nierich, A. P. (2020). An In Vitro Pilot Study Comparing the Novel HemoClear Gravity-Driven Microfiltration Cell Salvage System with the Conventional Centrifugal XTRA™ Autotransfusion Device. Anesthesiology research and practice, 20209584186. https://doi.org/10.1155/2020/9584186
Hoetink, Anneloes, et al. "An In Vitro Pilot Study Comparing the Novel HemoClear Gravity-Driven Microfiltration Cell Salvage System with the Conventional Centrifugal XTRA™ Autotransfusion Device." Anesthesiology research and practice vol. 2020 (2020): 9584186. doi: https://doi.org/10.1155/2020/9584186
Hoetink A, Scherphof SF, Mooi FJ, Westers P, van Dijk J, van de Leur SJ, Nierich AP. An In Vitro Pilot Study Comparing the Novel HemoClear Gravity-Driven Microfiltration Cell Salvage System with the Conventional Centrifugal XTRA™ Autotransfusion Device. Anesthesiol Res Pract. 2020 Sep 08;2020:9584186. doi: 10.1155/2020/9584186. eCollection 2020. PMID: 32963523; PMCID: PMC7495155.
Copy Download .nbib Format: NLM
The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments.

Cancer

Meijer AJM, Li KH, Brooks B, Clemens E, Ross CJ, Rassekh SR, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM, Carleton BC.
PMID: 34490624
Cancer. 2022 Jan 01;128(1):169-179. doi: 10.1002/cncr.33848. Epub 2021 Sep 07.

BACKGROUND: Ototoxicity is a common adverse event of cisplatin treatment. The authors investigated the development of cisplatin-induced hearing loss (CIHL) over time in children with cancer by age and examined the influence of other clinical characteristics on the course...

Cite
Meijer AJM, Li KH, Brooks B, et al. The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments. Cancer. 2021;128(1):169-179doi: 10.1002/cncr.33848.
Meijer, A. J. M., Li, K. H., Brooks, B., Clemens, E., Ross, C. J., Rassekh, S. R., Hoetink, A. E., van Grotel, M., van den Heuvel-Eibrink, M. M., & Carleton, B. C. (2022). The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments. Cancer, 128(1), 169-179. https://doi.org/10.1002/cncr.33848
Meijer, Annelot J M, et al. "The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments." Cancer vol. 128,1 (2022): 169-179. doi: https://doi.org/10.1002/cncr.33848
Meijer AJM, Li KH, Brooks B, Clemens E, Ross CJ, Rassekh SR, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM, Carleton BC. The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments. Cancer. 2022 Jan 01;128(1):169-179. doi: 10.1002/cncr.33848. Epub 2021 Sep 07. PMID: 34490624.
Copy Download .nbib Format: NLM
Outcomes After Lumbar Disk Herniation Surgery in the Dutch Population.

Global spine journal

Schepens MHJ, van Hooff ML, van Erkelens JA, Bartels R, Hoebink E, Smits M, Kuijpens JLP, van Limbeek J.
PMID: 33576274
Global Spine J. 2021 Feb 12;2192568221991124. doi: 10.1177/2192568221991124. Epub 2021 Feb 12.

STUDY DESIGN: Retrospective cohort study.OBJECTIVE: There is only limited data on the outcome of primary surgery of lumbar disk herniation (LDH) in Dutch patients. The objective of this study is to describe undesirable outcomes after primary LDH.METHODS: The National...

Cite
Schepens MHJ, van Hooff ML, van Erkelens JA, et al. Outcomes After Lumbar Disk Herniation Surgery in the Dutch Population. Global Spine J. 2021;2192568221991124doi: 10.1177/2192568221991124.
Schepens, M. H. J., van Hooff, M. L., van Erkelens, J. A., Bartels, R., Hoebink, E., Smits, M., Kuijpens, J. L. P., & van Limbeek, J. (2021). Outcomes After Lumbar Disk Herniation Surgery in the Dutch Population. Global spine journal, 2192568221991124. https://doi.org/10.1177/2192568221991124
Schepens, Maike H J, et al. "Outcomes After Lumbar Disk Herniation Surgery in the Dutch Population." Global spine journal vol. (2021): 2192568221991124. doi: https://doi.org/10.1177/2192568221991124
Schepens MHJ, van Hooff ML, van Erkelens JA, Bartels R, Hoebink E, Smits M, Kuijpens JLP, van Limbeek J. Outcomes After Lumbar Disk Herniation Surgery in the Dutch Population. Global Spine J. 2021 Feb 12;2192568221991124. doi: 10.1177/2192568221991124. Epub 2021 Feb 12. PMID: 33576274.
Copy Download .nbib Format: NLM
TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study.

NPJ precision oncology

Meijer AJM, Diepstraten FA, Langer T, Broer L, Domingo IK, Clemens E, Uitterlinden AG, de Vries ACH, van Grotel M, Vermeij WP, Ozinga RA, Binder H, Byrne J, van Dulmen-den Broeder E, Garrè ML, Grabow D, Kaatsch P, Kaiser M, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, Kepakova K, Tissing WJE, van der Kooi ALF, Kremer LCM, Kruseova J, Pluijm SMF, Kuehni CE, van der Pal HJH, Parfitt R, Spix C, Tillmanns A, Deuster D, Matulat P, Calaminus G, Hoetink AE, Elsner S, Gebauer J, Haupt R, Lackner H, Blattmann C, Neggers SJCMM, Rassekh SR, Wright GEB, Brooks B, Nagtegaal AP, Drögemöller BI, Ross CJD, Bhavsar AP, Am Zehnhoff-Dinnesen AG, Carleton BC, Zolk O, van den Heuvel-Eibrink MM.
PMID: 34262104
NPJ Precis Oncol. 2021 Jul 14;5(1):64. doi: 10.1038/s41698-021-00178-z.

In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) approach, we identified a genetic variant in TCERG1L (rs893507) to be associated with hearing loss...

Cite
Meijer AJM, Diepstraten FA, Langer T, et al. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ Precis Oncol. 2021;5(1):64doi: 10.1038/s41698-021-00178-z.
Meijer, A. J. M., Diepstraten, F. A., Langer, T., Broer, L., Domingo, I. K., Clemens, E., Uitterlinden, A. G., de Vries, A. C. H., van Grotel, M., Vermeij, W. P., Ozinga, R. A., Binder, H., Byrne, J., van Dulmen-den Broeder, E., Garrè, M. L., Grabow, D., Kaatsch, P., Kaiser, M., Kenborg, L., Winther, J. F., Rechnitzer, C., Hasle, H., Kepak, T., Kepakova, K., Tissing, W. J. E., van der Kooi, A. L. F., Kremer, L. C. M., Kruseova, J., Pluijm, S. M. F., Kuehni, C. E., van der Pal, H. J. H., Parfitt, R., Spix, C., Tillmanns, A., Deuster, D., Matulat, P., Calaminus, G., Hoetink, A. E., Elsner, S., Gebauer, J., Haupt, R., Lackner, H., Blattmann, C., Neggers, S. J. C. M. M., Rassekh, S. R., Wright, G. E. B., Brooks, B., Nagtegaal, A. P., Drögemöller, B. I., Ross, C. J. D., Bhavsar, A. P., Am Zehnhoff-Dinnesen, A. G., Carleton, B. C., Zolk, O., van den Heuvel-Eibrink, M. M. (2021). TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ precision oncology, 5(1), 64. https://doi.org/10.1038/s41698-021-00178-z
Meijer, A J M, et al. "TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study." NPJ precision oncology vol. 5,1 (2021): 64. doi: https://doi.org/10.1038/s41698-021-00178-z
Meijer AJM, Diepstraten FA, Langer T, Broer L, Domingo IK, Clemens E, Uitterlinden AG, de Vries ACH, van Grotel M, Vermeij WP, Ozinga RA, Binder H, Byrne J, van Dulmen-den Broeder E, Garrè ML, Grabow D, Kaatsch P, Kaiser M, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, Kepakova K, Tissing WJE, van der Kooi ALF, Kremer LCM, Kruseova J, Pluijm SMF, Kuehni CE, van der Pal HJH, Parfitt R, Spix C, Tillmanns A, Deuster D, Matulat P, Calaminus G, Hoetink AE, Elsner S, Gebauer J, Haupt R, Lackner H, Blattmann C, Neggers SJCMM, Rassekh SR, Wright GEB, Brooks B, Nagtegaal AP, Drögemöller BI, Ross CJD, Bhavsar AP, Am Zehnhoff-Dinnesen AG, Carleton BC, Zolk O, van den Heuvel-Eibrink MM. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ Precis Oncol. 2021 Jul 14;5(1):64. doi: 10.1038/s41698-021-00178-z. PMID: 34262104; PMCID: PMC8280110.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries